Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results

Table 1 Baseline characteristics of 508 patients who initiated simeprevir- and/or sofosbuvir-based therapy

	Total	SMV/SOF ± RBV	SOF/RBV	SOF/PEG/RBV
		Continuous: median (IQR)/categorical: n (%)
n	508	178	234	96
Age, yr	60 (54-64)	61 (57-65)	60 (54-65)	56 (50-62)
Race, black, n (%)	71 (14)	27 (15)	23 (10)	21 (22)
HCV genotype, n (%)
1	362 (71)	177 (99.4)	102 (44)	83 (87)
2	69 (14)	0 (0)	69 (29)	0 (0)
3	52 (10)	0 (0)	52 (22)	0 (0)
4	25 (5)	1 (0.6)	11 (5)	13 (14)
Gender, female	183 (37)	67 (39)	87 (39)	29 (31)
BMI, kg/m2	27.7 (24.7-30.8)	27.5 (24.5-30.2)	27.9 (2.6-31.0)	27.7 (25.1-31.1)
Diabetes, n (%)	111 (22)	29 (16)	59 (25)	23 (24)
Naïve to treatment, n (%)	204 (40)	51 (29)	114 (49)	39 (41)
PI failure, n (%)	89 (18)	48 (27)	18 (8)	23 (24)
HCV viral load, log U/mL	6.15 (5.61-6.58)	6.28 (5.78-6.74)	6.05 (5.43-6.50)	6.13 (5.63-6.53)
Hemoglobin, g/dL	13.8 (12.6-15.1)	13.9 (12.8-15.1)	13.5 (12.4-14.7)	14.7 (13.3-15.4)
Platelet, × 103/μL	143 (90-195)	146 (94-193)	125 (71-183)	180 (125-209)
ALT, U/L	63 (39-105)	72 (45-119)	59 (37-99)	60 (37-101)
AST, U/L	62 (38-99)	70 (40-113)	63 (38-101)	48 (33-83)
Total Bilirubin, mg/L	0.70 (0.50-1.10)	0.70 (0.50-1.00)	0.8 (0.5-1.5)	0.60 (0.40-0.83)
Albumin, g/dL	4.0 (3.5-4.4)	4.10 (3.70-4.40)	3.8 (3.2-4.3)	4.20 (3.80-4.45)
FIB-4 score	3.54 (1.73-6.72)	3.66 (1.90-5.99)	4.74 (1.91-9.89)	2.09 (1.46-3.85)
FIB-4 ≥ 3.25, n (%)	267 (54)	97 (56)	137 (61)	33 (34)

SMV: Simeprevir; SOF: Sofosbuvir; RBV: Ribavirin; PEG: Pegylated interferon; IQR: Interquartile range; BMI: Body mass index; PI: Protease inhibitor; HCV: Hepatitis C virus; ALT: Alanine transaminase; AST: Aspartate transaminase.